13 August 2024 | 9:20AM EDT Atara Biotherapeutics Inc. (ATRA): 20 EPS: CEO transition; First CD19 oncology data now in 1025, with autoimmune to follow In tandem with 2Q EPS, ATRA announced a CEO transition in which Cokey Nguyen (ATRA's Chief Scientific and Technical Officer) will succeed Pascal Touchon effective September 9. Further updates included delaying the timing for first Ph1 ATA3219 (allogeneic CD19 CAR T) data in relapsed/refractory B-cell non-Hodgkin's lymphoma to 1Q25 vs. 4Q24 prior on slower pat ...

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -148%. A quarter ago, it was expected that this drug developer would post a loss of $9.25 per share when it actually produced a loss of $5.75, delivering a surprise of 37.84%.Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------|--------------------------------------- ...

Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update Tab-cel ® U.S. BLA Accepted Under Priority Review With PDUFA Action Date of January 15, 2025 ATA3219 Lupus Nephritis and Severe Systemic Lupus Erythematosus Study Initiation Expected Q4 2024; Initial Clinical Data Expected Mid-2025 Enrolling ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 Effective September 9, 2024, Pascal Touchon To Assume Role of Chai ...

Atara Biotherapeutics (ATRA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.In ...

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.84%. A quarter ago, it was expected that this drug developer would post a loss of $0.61 per share when it actually produced a loss of $0.56, delivering a surprise of 8.20%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-0920988 (State or Other Jurisdiction o ...

Exhibit 99.1 Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned for Q4 2024, with Initial Clinical Data Expected in H2 2025 Enrolling ATA3219 Non-Hodgkin's Lymphoma Study, with Initial Clinical Data ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share, ATRA The Nasdaq Stock Market LLC FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Exhibit 99.1 Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024 Cash Runway Into 2027 Enables Key Pipeline Readouts | --- | ...